Kronox Lab Sciences Ltd
Incorporated in 2008, Kronox Lab Sciences Ltd manufactures High Purity Fine, inorganic chemicals, phosphate, and metallic chemicals[1]
- Market Cap ₹ 523 Cr.
- Current Price ₹ 141
- High / Low ₹ 229 / 130
- Stock P/E 20.2
- Book Value ₹ 27.3
- Dividend Yield 0.35 %
- ROCE 43.8 %
- ROE 32.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 24.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.9%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 50 | 62 | 82 | 96 | 90 | 100 | 100 | |
| 39 | 48 | 63 | 74 | 62 | 67 | 67 | |
| Operating Profit | 12 | 15 | 20 | 22 | 28 | 33 | 33 |
| OPM % | 23% | 24% | 24% | 23% | 32% | 33% | 33% |
| 1 | 1 | 1 | 2 | 2 | 3 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 2 | 2 | 2 | 1 | 1 | 2 |
| Profit before tax | 12 | 13 | 18 | 22 | 29 | 34 | 35 |
| Tax % | 27% | 26% | 26% | 26% | 25% | 26% | |
| 9 | 10 | 14 | 16 | 21 | 25 | 26 | |
| EPS in Rs | 343.60 | 403.73 | 565.56 | 4.42 | 5.75 | 6.86 | 6.95 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 7% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 23% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 36% |
| Last Year: | 33% |
Balance Sheet
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.24 | 0.24 | 37 | 37 | 37 | 37 |
| Reserves | 23 | 27 | 40 | 8 | 29 | 53 | 64 |
| 0 | 4 | 3 | 0 | 0 | 0 | 3 | |
| 11 | 7 | 13 | 9 | 8 | 9 | 9 | |
| Total Liabilities | 34 | 38 | 57 | 54 | 74 | 99 | 113 |
| 6 | 9 | 11 | 16 | 26 | 28 | 30 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 29 | 28 | 45 | 38 | 47 | 70 | 82 | |
| Total Assets | 34 | 38 | 57 | 54 | 74 | 99 | 113 |
Cash Flows
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 4 | 11 | 9 | 20 | 17 | 31 | |
| -4 | -3 | -8 | -7 | -17 | -28 | |
| -0 | -7 | -1 | -13 | 0 | -2 | |
| Net Cash Flow | 0 | 1 | 1 | -0 | 0 | 0 |
Ratios
Figures in Rs. Crores
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 90 | 114 | 71 | 72 | 72 |
| Inventory Days | 70 | 58 | 58 | 61 | 74 | 46 |
| Days Payable | 102 | 69 | 89 | 52 | 51 | 52 |
| Cash Conversion Cycle | 78 | 79 | 84 | 80 | 94 | 66 |
| Working Capital Days | 100 | 95 | 122 | 83 | 143 | 168 |
| ROCE % | 50% | 51% | 50% | 52% | 44% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Nov - Newspaper Announcement for Un-audited Financial Results for the Quarter and Half Year ended September 30, 2025
-
Unaudited Financial Results For The Quarter And Half Year Ended September, 2025
11 Nov - Board approved standalone unaudited Q2/H1 results to Sept 30,2025; PBT Rs1,773.45 lakh.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today
11 Nov - Approved unaudited Q2/H1 financials; PBT Rs1,773.45 lakh; final dividend 5% announced.
-
UPDATE ON DEVELOPMENT STATUS OF UNIT-IV
10 Nov - GPCB granted Consent to Establish for Unit‑IV at Dahej; construction to commence (dated Nov 10, 2025).
-
Board Meeting Intimation for Consider And Approve Unaudited Financial Results For The Quarte And Half Year Ended September 30, 2025
4 Nov - Board meeting on Nov 11, 2025 to approve Q2/H1 Sep 30, 2025 results; trading window closed.
Business Overview:[1][2]
KLSL is in High Purity Speciality Fine Chemicals Business with portfolio of about 185 products including Excipients and ingredients, High Purity Reagents, Pharmaceutical, nutraceutical and Food Chemical.